Enfusion, Inc. (NYSE:ENFN) COO Sells $31,788.12 in Stock

Enfusion, Inc. (NYSE:ENFN - Get Free Report) COO Neal Pawar sold 2,769 shares of the firm's stock in a transaction that occurred on Monday, March 3rd. The stock was sold at an average price of $11.48, for a total transaction of $31,788.12. Following the sale, the chief operating officer now owns 1,231,627 shares in the company, valued at approximately $14,139,077.96. The trade was a 0.22 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.

Neal Pawar also recently made the following trade(s):

• On Wednesday, March 5th, Neal Pawar sold 14,560 shares of Enfusion stock. The stock was sold at an average price of $11.38, for a total transaction of $165,692.80.
• On Wednesday, March 5th, Neal Pawar sold 14,560 shares of Enfusion stock. The stock was sold at an average price of $11.38, for a total transaction of $165,692.80.

Enfusion Stock Performance

ENFN traded down $0.06 during trading on Friday, reaching $11.24. 970,369 shares of the company traded hands, compared to its average volume of 1,164,913. Enfusion, Inc. has a 12-month low of $7.83 and a 12-month high of $11.80. The firm has a fifty day simple moving average of $10.98 and a 200 day simple moving average of $9.89. The company has a market cap of $1.44 billion, a P/E ratio of 280.95, a PEG ratio of 1.85 and a beta of 0.95.

Enfusion (NYSE:ENFN - Get Free Report) last posted its earnings results on Monday, March 3rd. The company reported $0.01 earnings per share for the quarter, missing analysts' consensus estimates of $0.03 by ($0.02). Enfusion had a net margin of 1.70% and a return on equity of 6.67%. The business had revenue of $52.94 million during the quarter, compared to analysts' expectations of $53.98 million. As a group, sell-side analysts expect that Enfusion, Inc. will post 0.06 earnings per share for the current fiscal year.

Remove Ads

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of the business. New York State Common Retirement Fund grew its holdings in shares of Enfusion by 23.8% in the fourth quarter. New York State Common Retirement Fund now owns 1,926,968 shares of the company's stock valued at $19,848,000 after purchasing an additional 370,498 shares in the last quarter. Geode Capital Management LLC grew its holdings in shares of Enfusion by 2.1% in the fourth quarter. Geode Capital Management LLC now owns 1,050,549 shares of the company's stock valued at $10,823,000 after purchasing an additional 21,183 shares in the last quarter. Wellington Management Group LLP grew its holdings in shares of Enfusion by 6.1% in the fourth quarter. Wellington Management Group LLP now owns 1,035,996 shares of the company's stock valued at $10,671,000 after purchasing an additional 59,700 shares in the last quarter. Azora Capital LP grew its holdings in shares of Enfusion by 3,255.9% in the fourth quarter. Azora Capital LP now owns 1,000,967 shares of the company's stock valued at $10,310,000 after purchasing an additional 971,140 shares in the last quarter. Finally, State Street Corp grew its holdings in shares of Enfusion by 2.3% in the third quarter. State Street Corp now owns 952,895 shares of the company's stock valued at $9,043,000 after purchasing an additional 21,729 shares in the last quarter. 81.05% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of equities research analysts have commented on ENFN shares. Stifel Nicolaus raised their target price on shares of Enfusion from $11.00 to $13.00 and gave the stock a "buy" rating in a research note on Wednesday, December 18th. William Blair reaffirmed a "market perform" rating on shares of Enfusion in a report on Monday, January 13th. Finally, Piper Sandler increased their price objective on shares of Enfusion from $10.00 to $11.50 and gave the company a "neutral" rating in a report on Monday, December 23rd. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and two have assigned a buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of "Hold" and a consensus target price of $11.13.

About Enfusion

Enfusion, Inc provides software-as-a-service solutions for investment management industry in the United States, Europe, the Middle East, Africa, and the Asia Pacific. The company provides Portfolio Management System, which generates a real-time investment book of record that consists of valuation and risk tools, which allows users to analyze aggregated or decomposed portfolio data for chief investment officers (CIOs) and portfolio managers; and Order and Execution Management System that enables portfolio managers, traders, compliance teams, and analysts to electronically communicate trade orders for a variety of asset classes, manage trade orders, and systemically enforce trading regulations and internal guidelines.